Published in Gene Therapy Weekly, February 10th, 2005
Abraxane (paclitaxel protein-bound particles for injectable suspension), a next generation taxane, and the first in a new class of albumin-bound nanotechnology, was approved for the treatment of metastatic breast cancer. U.S. Oncology conducted a phase 2 clinical trial of Abraxane in patients with metastatic breast cancer who were resistant to taxane drugs and continue to participate in the ongoing clinical development of the drug. Clinical trials of Abraxane have...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly